Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

Inclusion Criteria:

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study

- Age > 25 years

- Polypoidal choroidal vasculopathy as noted on fluorescein and ICG angiography: active
leakage, active bleeding or recent decrease in vision

- BCVA using ETDRS of 20/32 to 20/400

Exclusion Criteria:

- Any history of previous vitrectomy

- Any prior treatment with verteporfin photodynamic therapy in the study eye.

- Previous cataract surgery within the preceding 2 months of Day 0

- Active intraocular inflammation in the study eye

- Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
eye

- A condition that, in the opinion of the investigator, would preclude participation in
the study (e.g., unstable medical status including blood pressure, cardiovascular
disease)

- Participation in an investigational trial within 30 days of randomization that
involved treatment with any drug that has not received regulatory approval at the time
of study entry.

- Prior anti-vascular endothelial growth factor (VEGF) (Macugen, Avastin, Lucentis) in
the study eye prior within 30 days prior to enrollment in this study

- Known allergy to any component of the study drug

- Blood pressure >180/110 (systolic above 180 or diastolic above 110) If blood pressure
if brought below 180/110 by anti-hypertensive treatment, the patient can become
eligible.

- Major surgery within 28 days prior to randomization or major surgery planned within
the next 12 months. Major surgery is defined as a surgical procedure that is more
extensive than needle biopsy/aspiration placement of a central venous access device,
removal/biopsy of a skin lesion, or placement of a peripheral venous catheter.

- Myocardial infraction, other cardiac event requiring hospitalization, stroke,
transient ischemic attack, or treatment for acute congestive heart failure within 6
months prior to randomization.

- Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization.

- History of recurrent significant infections or bacterial infections

- Pregnancy (positive pregnancy test) or lactation

- Premenopausal women not using adequate contraception. The following are considered
effective means of contraception, surgical sterilization or use of oral
contraceptives, barrier contraception with either a condom or diaphragm in conjunction
with spermicide gel, an intra uterine device (IUD), or contraceptive hormone implant
or patch

- Prior enrollment in the study

- Any other condition that the investigator believes would pose a significant hazard to
the subject if the investigational therapy were initiated

- Participation in another simultaneous medical investigation or trial.